KAN.ST
Kancera AB (publ) [KAN.ST] Stock Forecast
Buy or Sell ? Support and Resistance
What is MACD and how to read it?
How RSI can help?
RSI : 000
KAN.ST Stock Summary
Top 10 Correlated ETFs
KAN.ST
Top 10 Correlated Stocks
KAN.ST
In the News
KAN.ST Financial details
Company Rating
Neutral
Market Cap
228.1M
Income
-64.89M
Revenue
592K
Book val./share
0.57
Cash/share
0.55
Dividend
-
Dividend %
-
Employees
3
Optionable
No
Shortable
Yes
Earnings
17 May 2024
P/E
-6.04
Forward P/E
-
PEG
5.32
P/S
589.9
P/B
5.52
P/C
2.7
P/FCF
-7.05
Quick Ratio
4.77
Current Ratio
4.94
Debt / Equity
-
LT Debt / Equity
-
-
-
EPS (TTM)
-0.78
EPS next Y
-
EPS next Q
-
EPS this Y
-9.09%
EPS next Y
-
EPS next 5Y
-
EPS last 5Y
-10.72%
Revenue last 5Y
-100%
Revenue Q/Q
-
EPS Q/Q
69.23%
-
-
-
-
SMA20
-
SMA50
-50%
SMA100
-50%
Inst Own
-
Inst Trans
-
ROA
-77%
ROE
-71%
ROC
-0.91%
Gross Margin
100%
Oper. Margin
-9698%
Profit Margin
-9763%
Payout
-
Shs Outstand
-
Shs Float
-
-
-
-
-
Target Price
-
52W Range
1.488-6.77
52W High
-75.23%
52W Low
+48.6%
RSI
37
Rel Volume
1.08
Avg Volume
324.48K
Volume
349.54K
Perf Week
-2.88%
Perf Month
-18.8%
Perf Quarter
-59.51%
Perf Half Y
-59.4%
-
-
-
-
Beta
1.428
-
-
Volatility
0.04%, 0.14%
Prev Close
-0.93%
Price
1.486
Change
-3.51%
KAN.ST Financial Performance
Yearly Fundamentals Overview
Last date of statement is 2023-12-31
| Metric | History | 2019-12-31 | 2020-12-31 | 2021-12-31 | 2022-12-31 | 2023-12-31 |
|---|---|---|---|---|---|---|
| 2.02K | 2.02K | 2.02K | 2.02K | 2.02K | ||
| Revenue per share | 0.13 | 0 | 0.03 | 0.01 | 0 | |
| Net income per share | -1.41 | -1.08 | -0.68 | -0.88 | -0.8 | |
| Operating cash flow per share | -1.3 | -1.05 | -0.66 | -0.8 | -0.68 | |
| Free cash flow per share | -1.3 | -1.05 | -0.66 | -0.8 | -0.68 | |
| Cash per share | 0.46 | 1.25 | 1.59 | 1.6 | 0.56 | |
| Book value per share | 0.68 | 1.64 | 1.83 | 1.8 | 0.58 | |
| Tangible book value per share | -0.26 | 1.17 | 1.52 | 1.44 | 0.58 | |
| Share holders equity per share | 0.68 | 1.64 | 1.83 | 1.8 | 0.58 | |
| Interest debt per share | 0.71 | 0.06 | 0.01 | 0 | 0 | |
| Market cap | 110.65M | 708.58M | 410.35M | 126.81M | 360.24M | |
| Enterprise value | 116.86M | 654.89M | 304.39M | 31.66M | 314.55M | |
| P/E ratio | -3.07 | -14.9 | -8.98 | -2.42 | -5.55 | |
| Price to sales ratio | 34.41 | 7.87K | 240.81 | 168.4 | 0 | |
| POCF ratio | -3.32 | -15.39 | -9.3 | -2.67 | -6.47 | |
| PFCF ratio | -3.32 | -15.39 | -9.3 | -2.67 | -6.47 | |
| P/B Ratio | 6.35 | 9.8 | 3.35 | 1.19 | 7.56 | |
| PTB ratio | 6.35 | 9.8 | 3.35 | 1.19 | 7.56 | |
| EV to sales | 36.34 | 7.28K | 178.64 | 42.04 | 0 | |
| Enterprise value over EBITDA | -3.27 | -13.83 | -6.71 | -0.61 | -4.99 | |
| EV to operating cash flow | -3.51 | -14.22 | -6.9 | -0.67 | -5.65 | |
| EV to free cash flow | -3.51 | -14.22 | -6.9 | -0.67 | -5.65 | |
| Earnings yield | -0.33 | -0.07 | -0.11 | -0.41 | -0.18 | |
| Free cash flow yield | -0.3 | -0.06 | -0.11 | -0.38 | -0.15 | |
| Debt to equity | 1.04 | 0.02 | 0 | 0 | 0 | |
| Debt to assets | 0.41 | 0.02 | 0 | 0 | 0 | |
| Net debt to EBITDA | -0.17 | 1.13 | 2.34 | 1.83 | 0.72 | |
| Current ratio | 0.6 | 6.22 | 10.74 | 7.2 | 2.65 | |
| Interest coverage | -166.61 | -42.32 | -2.66K | -440.12 | 0 | |
| Income quality | 0.93 | 0.99 | 0.97 | 0.91 | 0.86 | |
| Dividend Yield | 0 | 0 | 0 | 0 | 0 | |
| Payout ratio | 0 | 0 | 0 | 0 | 0 | |
| Sales general and administrative to revenue | 1.68 | 129.56 | 2.12 | 6.22 | 0 | |
| Research and developement to revenue | 10.73 | 436.43 | 25.02 | 60.57 | 0 | |
| Intangibles to total assets | 0.54 | 0.25 | 0.16 | 0.17 | 0 | |
| Capex to operating cash flow | 0 | 0 | 0 | 0 | 0 | |
| Capex to revenue | 0 | 0 | 0 | 0 | 0 | |
| Capex to depreciation | -0.01 | 0 | 0 | 0 | 0 | |
| Stock based compensation to revenue | 0 | 0 | 0 | 0 | 0 | |
| Graham number | 4.64 | 6.33 | 5.3 | 5.97 | 3.24 | |
| ROIC | -0.9 | -0.59 | -0.36 | -0.48 | -1.39 | |
| Return on tangible assets | -1.77 | -0.77 | -0.41 | -0.53 | -0.99 | |
| Graham Net | -0.49 | 1.11 | 1.47 | 1.42 | 0.36 | |
| Working capital | -10.53M | 51.33M | 101.6M | 85.66M | 29.66M | |
| Tangible asset value | -6.58M | 51.28M | 101.54M | 85.91M | 47.67M | |
| Net current asset value | -11.11M | 50.36M | 101.16M | 85.66M | 29.66M | |
| Invested capital | 1.04 | 0.02 | 0 | 0 | 0 | |
| Average receivables | 1.64M | 4.73M | 4.81M | 3.9M | 3.15M | |
| Average payables | 4.09M | 2.29M | 3M | 3.46M | 1.66M | |
| Average inventory | 0 | 0 | 117K | 117K | 0 | |
| Days sales outstanding | 373.06 | 25.01K | 740.28 | 2.1K | 0 | |
| Days payables outstanding | 8.25K | 32.55K | 4.11K | 3.37K | 0 | |
| Days of inventory on hand | 0 | 0 | 266.91 | 0 | 0 | |
| Receivables turnover | 0.98 | 0.01 | 0.49 | 0.17 | 0 | |
| Payables turnover | 0.04 | 0.01 | 0.09 | 0.11 | 0 | |
| Inventory turnover | 0 | 0 | 1.37 | 0 | 0 | |
| ROE | -2.07 | -0.66 | -0.37 | -0.49 | -1.36 | |
| Capex per share | 0 | 0 | 0 | 0 | 0 |
Quarterly Fundamentals Overview
Last date of statement is 2023-12-31 for Q4
| Metric | History | 2022-12-31 | 2023-03-31 | 2023-06-30 | 2023-09-30 | 2023-12-31 |
|---|---|---|---|---|---|---|
| 2.02K | 2.02K | 2.02K | 2.02K | 2.02K | ||
| Revenue per share | 0 | 0 | 0.01 | 0 | 0 | |
| Net income per share | -0.21 | -0.21 | -0.22 | -0.13 | -0.22 | |
| Operating cash flow per share | -0.14 | -0.23 | -0.18 | -0.1 | 0 | |
| Free cash flow per share | -0.14 | -0.23 | -0.18 | -0.1 | 0 | |
| Cash per share | 1.45 | 0.94 | 0.81 | 0.7 | 0.55 | |
| Book value per share | 1.63 | 1.1 | 0.93 | 0.79 | 0.57 | |
| Tangible book value per share | 1.31 | 0.84 | 0.68 | 0.58 | 0.57 | |
| Share holders equity per share | 1.63 | 1.1 | 0.93 | 0.79 | 0.57 | |
| Interest debt per share | 0 | 0 | 0 | 0 | 0 | |
| Market cap | 139.98M | 278.83M | 203.19M | 438.03M | 368.78M | |
| Enterprise value | 44.83M | 202.7M | 136.22M | 379.81M | 323.09M | |
| P/E ratio | -2.5 | -3.98 | -2.79 | -10.2 | -4.99 | |
| Price to sales ratio | 5.18K | 2.05K | 445.6 | 0 | 0 | |
| POCF ratio | -15.16 | -14.67 | -13.74 | -50.05 | 0 | |
| PFCF ratio | -15.16 | -14.67 | -13.74 | -50.05 | 0 | |
| P/B Ratio | 1.31 | 3.12 | 2.64 | 6.63 | 7.74 | |
| PTB ratio | 1.31 | 3.12 | 2.64 | 6.63 | 7.74 | |
| EV to sales | 1.66K | 1.49K | 298.73 | 0 | 0 | |
| Enterprise value over EBITDA | -3.13 | -11.86 | -7.62 | -36.42 | -16.63 | |
| EV to operating cash flow | -4.85 | -10.67 | -9.21 | -43.4 | 0 | |
| EV to free cash flow | -4.85 | -10.67 | -9.21 | -43.4 | 0 | |
| Earnings yield | -0.1 | -0.06 | -0.09 | -0.02 | -0.05 | |
| Free cash flow yield | -0.07 | -0.07 | -0.07 | -0.02 | 0 | |
| Debt to equity | 0 | 0 | 0 | 0 | 0 | |
| Debt to assets | 0 | 0 | 0 | 0 | 0 | |
| Net debt to EBITDA | 6.65 | 4.45 | 3.75 | 5.58 | 2.35 | |
| Current ratio | 7.2 | 5.45 | 4.82 | 4.94 | 2.65 | |
| Interest coverage | -367.71 | -55.09 | -84.05 | -44.5 | 0 | |
| Income quality | 0.66 | 1.09 | 0.81 | 0.82 | 0 | |
| Dividend Yield | 0 | 0 | 0 | 0 | 0 | |
| Payout ratio | 0 | 0 | 0 | 0 | 0 | |
| Sales general and administrative to revenue | 47.89 | 12.77 | 3.82 | 0 | 0 | |
| Research and developement to revenue | 429.44 | 111.53 | 36.29 | 0 | 0 | |
| Intangibles to total assets | 0.17 | 0.2 | 0.23 | 0.23 | 0 | |
| Capex to operating cash flow | 0 | 0 | 0 | 0 | 0 | |
| Capex to revenue | 0 | 0 | 0 | 0 | 0 | |
| Capex to depreciation | 0 | 0 | 0 | 0 | 0 | |
| Stock based compensation to revenue | 0 | 0 | 0 | 0 | 0 | |
| Graham number | 2.79 | 2.3 | 2.16 | 1.51 | 1.69 | |
| ROIC | -0.13 | -0.19 | -0.24 | -0.16 | -0.41 | |
| Return on tangible assets | -0.14 | -0.21 | -0.26 | -0.18 | -0.28 | |
| Graham Net | 1.29 | 0.82 | 0.67 | 0.57 | 0.35 | |
| Working capital | 85.66M | 68.26M | 55.78M | 48.12M | 29.66M | |
| Tangible asset value | 85.91M | 68.41M | 55.85M | 48.12M | 47.67M | |
| Net current asset value | 85.66M | 68.26M | 55.78M | 48.12M | 29.66M | |
| Invested capital | 0 | 0 | 0 | 0 | 0 | |
| Average receivables | 4.53M | 5.89M | 5.42M | 2.75M | 2.02M | |
| Average payables | 1.66M | 1.66M | 0 | 0 | 0 | |
| Average inventory | 0 | 0 | 0 | 0 | 0 | |
| Days sales outstanding | 14.47K | 4.93K | 670.07 | 0 | 0 | |
| Days payables outstanding | 3.33K | 0 | 0 | 0 | 0 | |
| Days of inventory on hand | 0 | 0 | 0 | 0 | 0 | |
| Receivables turnover | 0.01 | 0.02 | 0.13 | 0 | 0 | |
| Payables turnover | 0.03 | 0 | 0 | 0 | 0 | |
| Inventory turnover | 0 | 0 | 0 | 0 | 0 | |
| ROE | -0.13 | -0.2 | -0.24 | -0.16 | -0.39 | |
| Capex per share | 0 | 0 | 0 | 0 | 0 |
KAN.ST Frequently Asked Questions
What is Kancera AB (publ) stock symbol ?
Kancera AB (publ) is a SE stock and trading under the symbol KAN.ST
What is Kancera AB (publ) stock quote today ?
Kancera AB (publ) stock price is $1.486 today.
Is Kancera AB (publ) stock public?
Yes, Kancera AB (publ) is a publicly traded company.
Company Profile
- Volume Average 324.48K
- Market Capitalization 228.1M
- Employee 3
- CEO Mr. Peter Selin
- Headquarters Solna,SE
- IPO Date 2011-02-25
-
Website
https://www.kancera.com 
Kancera AB (Publ) develops drugs for inflammatory diseases and cancer in Sweden and internationally. The company is developing small molecule drug candidates KAND567, which is in phase IIa clinical trial for inflammatory heart disease following infarction, as well as KAND145, which is in phase I study in healthy subjects to document desired dose levels against cancer; and Phase IIa study for the treatment of ovarian cancer. It also develops HDAC for the treatment of nerve inflammation and pain; and ROR1 inhibitors for the treatment of solid tumors and blood cancers. Kancera AB (Publ) was founded in 2010 and is based in Solna, Sweden.
